Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir

Clinical Pharmacokinetics

Volumn 44, Issue 10, 2005, Pages 1035-1050

  Le Tiec, Clotilde ^a   Barrail, Aurélie ^a   Goujard, Cécile ^a   Taburet, Anne Marie ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; AMPRENAVIR; ANTACID AGENT; ATAZANAVIR; CLARITHROMYCIN; DELAVIRDINE; DIDANOSINE; DILTIAZEM; EFAVIRENZ; ERGOT ALKALOID; ETHINYLESTRADIOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; KETOCONAZOLE; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NORETHISTERONE; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; RIFABUTIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY FLUID; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; EUROPE; EXPECTANCY; EXPERIENCE; FOOD; GASTROINTESTINAL TOXICITY; HEADACHE; HEMODIALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; IC 50; JAUNDICE; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LOW DRUG DOSE; MEAL; NAUSEA; NONHUMAN; POPULATION; PREGNANCY; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SEX; STEADY STATE; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES; WILD TYPE;

ADENINE; AGE FACTORS; CLINICAL TRIALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LIVER; OLIGOPEPTIDES; OXAZINES; PHOSPHONIC ACIDS; PYRIDINES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; SEX FACTORS;

EID: 25144448034     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200544100-00003     Document Type: Review

References (81)

1. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA panel. JAMA 2000; 283: 381-90
2. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998; 279: 450-4
3. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA panel. JAMA 2004; 292: 251-65
4. Delfraissy JF. Prise en charge thérapeutique des personnes infectées par le VIH: recommandations du groupe d'experts. Paris: Médecine-Sciences Flammarion, 2004
5. Department of Health And Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [online]. Available from URL: http://aidsinfo.nih.gov/guidelines [Accessed 2005 Jul 6]
6. Taburet AM, Paci-Bonaventure S, Peytavin G, et al. Once-daily administration of antiretrovirals: pharmacokinetics of emerging therapies. Clin Pharmacokinet 2003; 42 (14): 1179-91
7. Ena J, Pasquau F. Once a day highly active antiretroviral therapy: a systematic review. Clin Infect Dis 2003; 36 (1): 1186-90
8. FDA. CDER new and generic drug approvals 1998-2004: Reyataz™ [online]. Available from URL: http://www.fda.gov/cder/foi/label/2003/ 21567_reyataz_lbl.pdf [Accessed 2005 Aug 22]
9. European Medicines Agency. EMEA label [online]. Available from URL: http://www.emea.eu.int/humandocs/Humans/EPAR/reyataz/reyataz.htm [Accessed 2005 Aug 22]
10. Goldsmith DR, Perry CM. Atazanavir. Drugs 2003; 63 (16): 1679-93
11. Murphy RL. Reviving protease inhibitors: new data and more options. J Acquir Immune Defic Syndr 2003; 33: S43-56
12. Havlir DV, O'Marro SD. Atazanavir: new option for treatment of HIV infection. Clin Infect Dis 2004; 38: 1599-604
13. Schuster A, Burzawa S, Jemal M, et al. Quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human plasma by liquid chromatography-tandem mass spectrometry following automated solid-phase extraction. J Chromatogr B 2003; 788: 377-86
14. Proust V, Toth K, Hulin A, et al. Simultaneous high-performance liquid chromatographic determination of antiretroviral agents amprenavir, nelfinavir, ritonavir, saquinavir, delavirdine and efavirenz in human plasma. J Chromatogr B 2000; 742: 453-8
15. Keil K, Frerichs VA, DiFrancesco R, et al. Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma. Ther Drug Monit 2003 Jun; 25 (3): 340-6
16. Poirier JM, Robidou P, Jaillon P. Simultaneous determination of the six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) plus M8 nelfinavir metabolite and the non-nucleoside reverse transcription inhibitor efavirenz in human plasma by solid-phase extraction and column liquid chromatography. Ther Drug Monit 2002 Apr; 24 (2): 302-9
17. Jemal M, Rao S, Gatz M, et al. Liquid chromatography-tandem mass spectrometric quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human peripheral blood mononuclear cells (PBMC): practical approaches to PBMC preparation and PBMC assay design for high-throughput analysis. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 795: 273-89
18. Colombo S, Beguin A, Telenti A, et al. Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 819 (2): 259-76
19. King JR, Wynn H, Brundage R, et al. Pharmacokinetic enhancement of protease inhibitor therapy. Clin Pharmacokinet 2004; 43: 291-310
20. O'Mara M, Smith J, Olsen SJ, et al. BMS-232632: single oral dose safety and pharmacokinetic study in healthy volunteers [abstract no. I-242]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; San Diego (CA)
21. Randall D, Agarwala S, Mummanemi V, et al. Multiple-dose pharmacokinetics of atazanavir in healthy subjects: a summary of food effect and drug interaction studies [abstract no. H1717]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27-30; San Diego (CA)
22. Bailey DG, Malcolm J, Arnold O, et al. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998; 46: 101-10
23. Randall D, Agarwala S, Mummanemi V, et al. Tissue compartment concentrations of atazanavir in cerebrospinal fluid, seminal fluid and plasma in HIV+subjects [abstract no. H-1711]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27-30; San Diego (CA)
24. Kim RB. Drug transporters in HIV therapy. Top HIV Med 2003; 11 (4): 136-9
25. Agarwala S, Grasela D, Child M, et al. Characterization of the steady-state pharmacokinetic (PK) profile of atazanavir (ATV) beyond the 24-hour dosing interval [abstract no. 845]. 8th Conference on Retroviruses and Opportunistic infections; 2001 Feb 4-8; Chicago (IL)
26. O'Mara E, Piliero P, Drusano G, et al. BMS-232632: a preliminary pharmacokinetic and pharmacodynamic evaluation of BMS-232632 in a protease inhibitor naïve HIV+ population [abstract no. P9]. AIDS 2000; 14 Suppl. 4: S19
27. Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavir/ritonavir and tenofovir in heavily pretreated HIV-infected patients. Antimicrob Agents Chemother 2004; 48: 2091-6
28. Agarwala S, Russo R, Mummaneni V, et al. Steady state pharmacokinetic interaction study of atazanavir with ritonavir in healthy subjects [abstract no. H1716]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27-30; San Diego (CA)
29. O'Mara E, Randall D, Stoltz R, et al. BMS-232632: a prospective study of age and gender effects on the single-dose pharmacokinetics in healthy volunteers [abstract no. 180]. 1st International AIDS Society Conference; 2001 Jul 8-11; Buenos Aires
30. Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet 2004; 43 (15): 1071-87
31. Taburet AM, Gerard L, Legrand M, et al. Antiretroviral drug removal by haemodialysis. AIDS 2000; 14: 902-3
32. Paci-Bonaventure S, Hafi A, Vincent I, et al. Lack of removal of nelfinavir during a hemodialysis session in an HIV-1 infected patient with hepatic and renal insufficiency. Nephrol Dial Transplant 2001; 16: 642-3
33. De Maat MM, Ekhart GC, Huitema AD, et al. Drug interactions between antiretroviral drugs and comedicated agents. Clin Pharmacokinet 2003; 42: 223-82
34. Kaul S, Bassi K, Damle B, et al. Pharmacokinetic (PK) evaluation of the combination of atazanavir (ATV), enteric coated didanosine (ddI-EC), and tenofovir disoproxil fumarate (TDF) for a once-daily antiretroviral regimen [abstract no. A-1616]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14-17; Chicago (IL)
35. Preston S, Piliero P, O'Mara E, et al. Evaluation of the steady state interaction between atazanavir (ATV) and efavirenz (EFV) [abstract no. 443]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24-28; Seattle (WA)
36. O'Mara E, Agarwala S, Randall D, et al. Steady state pharmacokinetic interaction study of atazanavir (ATV) with efavirenz (EFV) and ritonavir (RTV) in healthy subjects [abstract no. 444]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24-28; Seattle (WA)
37. Seminari E, Guffanti M, Villani P, et al. Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients. Eur J Clin Pharmacol. Epub 2005 Jul 23
38. Mummaneni V, Randall D, Geraldes M, et al. Steady state pharmacokinetic (PK) interaction study of atazanavir (ATV) with fixed-dose lamivudine (3TC) and zidovudine (ZDV) in healthy subjects [abstract no. H-1713]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27-30; San Diego (CA)
39. Murphy RL, Sanne I, Cahn P, et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 2003; 17: 2603-14
40. Fletcher CV, Acosta EP, Cheng H, et al. Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884. AIDS 2000; 14: 2495-501
41. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005; 19 (7): 685-94
42. Barry M, Mulcahy F, Merry C, et al. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 1999; 36: 289-30
43. Smith PF, DiCenzo R, Morse G. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet 2001; 40: 893-905
44. Back D, Gibbons S, Khoo S. Pharmacokinetic drug interactions with nevirapine. J Acquir Immune Defic Syndr 2003; 34 Suppl. 1: S8-14
45. Winston A, Bloch M, Carr A, et al. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy. J Antimicrob Chemother. Epub 2005 Jul 4
46. O'Mara E, Mummaneni V, Bifano M, et al. Steady-state pharmacokinetic interaction study between BMS-232632 and ritonavir in healthy subjects [abstract no. 740]. 8th Conference on Retroviruses and Opportunistic Infections; 2001 Feb 4-8; Chicago (IL)
47. Cooper CL, van Heeswijk RPG, Gallicano K, et al. A review of low-dose ritonavir in protease inhibitor combinaison therapy. Clin Infect Dis 2003; 36: 1585-92
48. Moyle GJ, Back D. Principle and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2001; 2: 105-13
49. O'Mara E, Mummaneni V, Randall D, et al. BMS-232632: single-oral dose-safety and drug interaction studies in healthy subjects [abstract no. 504]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 4; San Francisco (CA)
50. Kilby JM, Sfakianos G, Gizzi N, et al. Safety and pharmacokinetics of once-daily regimens of softgel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. Antimicrob Agents Chemother 2000; 44: 2672-8
51. Cardiello PG, Monhaphol T, Mahanontharit A, et al. Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects. J Acquir Immune Defic Syndr 2003; 32: 375-9
52. Schutz M, Sargent S, Kakuda T. Optimizing dosing strategies for the combination of atazanavir plus saquinavir. AIDS 2004; 18: 704-5
53. Boffito M, Kurowski M, Kruse G, et al. Atazanavir enhances saquinavir hardgel concentrations in a ritonavir-boosted once-daily regimen. AIDS 2004; 18: 1291-7
54. Guffanti M, De Pascalis CR, Seminari E, et al. Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pretreated HIV-positive patients. AIDS 2003; 17: 2669-71
55. Tran JQ, Petersen C, Garrett M, et al. Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir. Clin Pharmacol Ther 2002; 72: 615-26
56. Taburet AM, Raguin G, Le Tiec C, et al. Interactions between amprenavir and the lopinavir/ritonavir combination in heavily pretreated HIV-infected patients. The ANRS Protocol 104 (Puzzle 1) Investigators. Clin Pharmacol Ther 2004; 75: 310-23
57. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38: 41-57
58. Agarwala S, Mummaneni V, Randall D, et al. Pharmacokinetic (PK) effect of rifabutin (RIF) on atazanavir (ATV) with and without ritonavir (RTV) in healthy subjects [abstract no. 445]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24-28; Seattle (WA)
59. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: similarities and differences. Clin Pharmacokinet 1997; 32: 403-25
60. O'Mara E, Randall D, Uderman H, et al. Steady-state pharmacokinetic interaction study between BMS-232632 and ketoconazole in healthy subjects. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto (ON)
61. Niemi M, Backman JT, Fromm MF, et al. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003; 42: 779-862
62. Drusano GL, Bilello JA, Preston SL, et al. Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable. J Infect Dis 2001; 183 (7):1126-9
63. Piliero PJ. The utility of inhibitory quotients in determining the relative potency of protease inhibitors. AIDS 2002; 16: 799-800
64. Colonno RJ, Thiry A, Limoli K, et al. Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrob Agents Chemother 2003; 47 (4): 1324-33
65. Colonno R, Rose R, McLaren C, et al. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J Infect Dis 2004; 189: 1802-10
66. Schnell T, Schmidt B, Moschik G, et al. Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir and atazanavir in a panel of clinical samples. AIDS 2003; 17 (8): 1258-61
67. 50 ratio: call for consensus. J Acquir Immune Defic Syndr 2001; 27: 210-1
68. Sanne I, Piliero P, Squires K, et al. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naïve subjects. J Acquir Immune Defic Syndr 2003; 32: 18-29
69. Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004; 36: 1011-9
70. Haas DW, Zala C, Schrader S, et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. AIDS 2003; 17: 1339-49
71. Nieto-Cisneros L, Zala C, Fessel WJ, et al. Antiviral efficacy, metabolic changes and safety of atazanavir versus lopinavir/ ritonavir in combination with two NRTIs in patients who have experienced virological failure with prior PI-containing regimen(s): 24 week results from BMS AI424-043 [abstract no. 117]. 2nd IAS conference on HIV pathogenesis and treatment; 2003 Jul 13-16; Paris
72. Carr A, Samarars K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12 (7): F51-8
73. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999; 13: 2493-505
74. Sulkowski MS. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis 2004; 38 Suppl. 2: S90-7
75. O'Mara E, Mummaneni V, Burchell B, et al. Relationship between uridine diphosphate-gluronosyl transferase (UDP-GT)1A1 genotype and total bilirubin elevations in healthy subjects receiving BMS-232632 and saquinavir [abstract no. 1645]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto (ON)
76. Eholie SP, Lacombe K, Serfaty L, et al. Acute hepatic cytolysis in an HIV-infected patient taking atazanavir. AIDS 2004; 18: 1610-1
77. Wood R, Phanuphak P, Cahn P, et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr 2004; 36: 684-92
78. Haerter G, Manfras BJ, Mueller M, et al. Regression of lipodystrophy in HIV-infected patients under therapy with the new protease inhibitor atazanavir. AIDS 2004; 18: 952-5
79. Aarnoutse RE, Schapiro JM, Boucher CAB, et al. Therapeutic drug monitoring: an aid to optimizing response to antiretroviral drugs? Drugs 2003; 63: 741-53
80. Barrios A, Rendon AL, Rios P, et al. Atazanavir plasma levels are associated with efficacy and safety in protease inhibitor-experienced HIV-infected patients [abstract no. 606]. 11th Conference on Retroviruses and Opportunistic Infections; San Francisco (CA)
81. Back D, Gatti G, Fletcher C, et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 2002; 16 Suppl. 1: S5-37